Drawing for SNOW BRAND

USPTO serial 75447944

SNOW BRAND

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
SHANAHAN, PATRICK
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SNOW BRAND?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

JESS M COLLEN

JESS M COLLEN COLLEN LAW ASSOCIATES PCMEMBER MCGLEW AND TUTTLEP O BOX 306SCARBOROUGH, NY 10510-0806

Goods and services

ClassDescriptionStatusFirst use
001Chemical products, namely, carbohydrates, proteins and enzymes; surface active agents, namely, emulsifiers, dispersants, penetrants, wetting agents, softening agents, anti-static agents, water repellants, defoaming agents, foaming agents, degreasing agents, decoloring agents, absorbents, and rust inhibitors; stabilizers for soil; n-acetylneuraminic acid, erythropoietin, epidermal growth factor, plant growth regulating preparations, namely, chemicals for plant growing, hormones for plants, soil conditioning chemicals, anti-sprouting preparations for plantsACTIVE—
005Drugs affecting the central nervous system, namely, central stimulants, antipyretic-analgesic drugs, anti-epileptics, stimulants, hypnotics, sedatives, general anesthetics, and anti-vertigo agents; drugs affecting peripheral nervous systems, namely, local anesthetics, muscle relaxants, anti-hydrotics, medicine for autonomic nerves, anti-spasmodics, and diaphoretics; drugs affecting the sensory organs, namely, medicine for opthamology and otolaryngology; drugs used to combat allergies, namely, antihistaminics, torpents, sodium chromogolicates, tranilasts, and amlexanoxes; drugs affecting circulatory organs, namely, cardiotonics, antihypertensive agents, angiotonics, capillary stabilizers, cerebral hemorrhage preventives, antirythmic agents, and diuretics; agents affecting respiratory organs, namely, respiratory stimulants, antitussive candies, and antitussive expectorants; agents affecting digestive organs, namely, gastroloavage agents, enemas, laxatives, stomach digestives, buccal preparations, stomatic cleaning agents, stomatic algefacients, emetics, dental preparations, gestric antacides, medicine for controlling intestinal functions, antiemetics, castor oils, dental caries preventives, and cholagogues; hormone preparations; agents for urinary, genital and anal organs, namely, oxytonics, medicine for hemorrhoids, emmenagogues, disinfectants for urinary tracts, and contraceptives; agents affecting the epidermis, namely, medicine for purulent disorders, medicine for parasitic dermatosis, astringents, anti-inflammatory agents, analgesics, antipruritics, trichosanthes roots, medicinal soaps, emollients, medicines for thrix, medicinal baby oils or baby oil for medical uses, medicinal baby powder or baby powder for medical uses, and bath medicines; vitamin preparations; amino acids and preparations, namely, threonines, tryptophans, methionines and lysines; nutrients, tonics and alternatives, namely, royal jellies, culcium preparations, chondroitin preparations, nutrient supplements, organ preparations, protein-amino acid preparations, saccarides preparations, mineral preparations, medicinal liquars and organic acid preparations; agents relating to the blood, namely, anti-coagulation agents, blood substitutes or plasma substitutes, plasma and hemostatics; agents affecting metabolism, namely, antidotes, enzyme preparations, lactogenic agents, choline preparations and habituations; agents activating cellular function chlorophyl preparations, namely, chlorophyll preparations and pigment preparations; tumor suppressing agents, namely, medicines for cancer and medicine for sarcoma; agent used in lesion due to physical stimuli, namely, medicines for heatstroke and medicines for radiodisorder; agents used in lesion due to chemical stimuli, namely, medicines for chloric toxicosis, medicines for arsenical toxicosis and medicine for benzol toxicosis; antibiotics; chemotherapeutics; biological products, namely, antimicrobial serums, anti toxic agents, mixing preparations, preparations for biological examination, toxoids and vaccines; agents against parasites, namely, anthelmintics and anti protozoan agents; agents for dispensing use, namely, flavoring agents, coloring agents, ointment bases, or base for ointments, excipients, solbilizing agents; diagnostic aids, namely, x-ray contrast mediums, diagnostics reagents, and diagnostic mediums; isotope labeled material for medical and diagnostic use; narcotics, namely, opium alkaloid preparations, synthetic dopes, and coca alkaloid preparations; veterinary medicines, namely, animal washes, anti-horse-fly oils, bacteriological or bacterial preparations for veterinary use, biological preparations for veterinary purposes, cattle washes, chemical preparations for veterinary purposes, chemical reagents for veterinary purposes, cultures of microorganisms for veterinary use, enzymes for veterinary purposes, greases for veterinary purposes, lotions for veterinary purposes, dog lotions, dog washes, repellants for dogs, medicines for veterinary purposes, preparations of microorganisms for veterinary use, preparations of trace elements for animal use, preparations for destroying noxious animals, vermin destroying preparations; disinfectants, namely, preparations for destroying dry rot fungus, fugicides, germicides, disinfectants for hygiene purposes, sterilizing preparations, and soil-sterilizing preparations; insecticides, fumigants; rodenticides; herbicides; moth repellants; deodorants, namely, deodorants other than for personal use and antibromics; antiseptics; mosquito-repellant incense; medicines for sjogren syndrome; medicines for alzheimer disease or senile dementia; medicines for liver complaints, namely, L-methionine, thioctic acid, and sodium glucuronate; semen for artificial inseminationACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 14, 2012ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Oct 1, 2001ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 2, 2001NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Oct 10, 2000PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 8, 2000NPUBNOTICE OF PUBLICATION—
Aug 7, 2000CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 5, 2000CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 5, 200044EASEC. 44(E) CLAIM ADDED—
Nov 5, 1999CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 3, 1999CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 4, 1998CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 29, 1998DOCKASSIGNED TO EXAMINER—
Oct 28, 1998DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance